Cinctive Capital Management LP acquired a new stake in Xylem Inc. (NYSE:XYL - Free Report) during the first quarter, according to its most recent filing with the SEC. The firm acquired 10,461 shares of the industrial products company's stock, valued at approximately $1,250,000.
Several other institutional investors also recently made changes to their positions in XYL. Price T Rowe Associates Inc. MD boosted its position in shares of Xylem by 689.5% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,708,963 shares of the industrial products company's stock worth $443,074,000 after purchasing an additional 3,239,203 shares in the last quarter. Nuveen LLC purchased a new stake in shares of Xylem during the 1st quarter worth $99,726,000. OVERSEA CHINESE BANKING Corp Ltd boosted its position in shares of Xylem by 390.5% during the 1st quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 1,021,337 shares of the industrial products company's stock worth $122,009,000 after purchasing an additional 813,100 shares in the last quarter. Vaughan Nelson Investment Management L.P. purchased a new stake in shares of Xylem during the 1st quarter worth $89,828,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in shares of Xylem during the 4th quarter worth $83,139,000. 87.96% of the stock is currently owned by hedge funds and other institutional investors.
Xylem Trading Up 1.5%
Shares of XYL stock opened at $141.84 on Friday. The firm has a 50-day moving average price of $137.11 and a 200 day moving average price of $127.17. Xylem Inc. has a twelve month low of $100.47 and a twelve month high of $145.33. The company has a market capitalization of $34.52 billion, a price-to-earnings ratio of 36.84, a PEG ratio of 2.42 and a beta of 1.09. The company has a current ratio of 1.90, a quick ratio of 1.43 and a debt-to-equity ratio of 0.17.
Xylem (NYSE:XYL - Get Free Report) last announced its earnings results on Thursday, July 31st. The industrial products company reported $1.26 earnings per share for the quarter, beating the consensus estimate of $1.15 by $0.11. Xylem had a net margin of 10.74% and a return on equity of 10.33%. The firm had revenue of $2.30 billion during the quarter, compared to the consensus estimate of $2.20 billion. During the same quarter in the previous year, the company posted $1.09 EPS. The firm's revenue for the quarter was up 6.1% on a year-over-year basis. Xylem has set its FY 2025 guidance at 4.700-4.850 EPS. Research analysts forecast that Xylem Inc. will post 4.65 earnings per share for the current fiscal year.
Xylem Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 25th. Stockholders of record on Thursday, August 28th will be paid a dividend of $0.40 per share. The ex-dividend date of this dividend is Thursday, August 28th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 1.1%. Xylem's dividend payout ratio is currently 41.56%.
Analysts Set New Price Targets
Several brokerages have commented on XYL. Raymond James Financial upgraded shares of Xylem to a "hold" rating in a research report on Thursday, May 15th. Cowen restated a "hold" rating on shares of Xylem in a research report on Tuesday, August 26th. TD Cowen boosted their target price on shares of Xylem from $125.00 to $130.00 and gave the stock a "hold" rating in a research report on Tuesday, August 26th. JPMorgan Chase & Co. started coverage on Xylem in a research note on Friday, May 30th. They set an "overweight" rating and a $148.00 price target for the company. Finally, Citigroup reaffirmed a "buy" rating and set a $152.00 price target (up previously from $137.00) on shares of Xylem in a research note on Monday, July 14th. Six research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $152.29.
Get Our Latest Stock Report on Xylem
About Xylem
(
Free Report)
Xylem Inc, together with its subsidiaries, engages in the design, manufacture, and servicing of engineered products and solutions worldwide. It operates through four segments: Water Infrastructure, Applied Water, Measurement & Control Solutions, and Integrated Solutions and Services. The Water Infrastructure segment offers products, including water, storm water, and wastewater pumps; controls and systems; filtration, disinfection, and biological treatment equipment; and mobile dewatering equipment and rental services under the ADI, Flygt, Godwin, Sanitaire, Magneto, Neptune Benson, Ionpure, Leopold, Wedeco, and Xylem Vue brands.
Featured Stories
Want to see what other hedge funds are holding XYL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xylem Inc. (NYSE:XYL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Xylem, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xylem wasn't on the list.
While Xylem currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.